SCHEMBL4238109

SCHEMBL4238109

NC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(O)c2)ccn1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 10/20 0.82
KDR P35968 8/20 0.67
BRAF P15056 6/20 0.67
RET P07949 3/20 0.67
RIPK2 O43353 2/20 0.67
ABCB11 O95342 2/20 0.67
ABL1 P00519 2/20 0.67
HTR1A P08908 2/20 0.67
PDGFRB P09619 2/20 0.67
ADORA3 P0DMS8 2/20 0.67
KIT P10721 2/20 0.67
FGFR1 P11362 2/20 0.67
PDGFRA P16234 2/20 0.67
FLT1 P17948 2/20 0.67
MAOA P21397 2/20 0.67
EPHA1 P21709 2/20 0.67
TBXA2R P21731 2/20 0.67
EPHA2 P29317 2/20 0.67
TTK P33981 2/20 0.67
EPHX2 P34913 2/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29643339 0.91 RAF1 (0.82) RAF1KDRBRAFRETRIPK2
SCHEMBL432444 0.91 RAF1 (0.82) RAF1KDRBRAFRETRIPK2
SCHEMBL29918250 0.91 RAF1 (1.00) RAF1KDRBRAFRETRIPK2
SCHEMBL548133 0.91 RAF1 (1.00) RAF1KDRBRAFRETRIPK2
SCHEMBL4244820 0.87 RAF1 (0.79) RAF1KDRBRAFRETRIPK2
SCHEMBL939087 0.87 RAF1 (0.85) RAF1KDRBRAFRETRIPK2
SCHEMBL9926366 0.83 RAF1 (0.85) RAF1KDRBRAFRETRIPK2
SCHEMBL3408496 0.83 RAF1 (0.85) RAF1KDRBRAFRETRIPK2
SCHEMBL3405012 0.83 RAF1 (0.85) RAF1KDRBRAFRETRIPK2
SCHEMBL9926369 0.83 RAF1 (0.85) RAF1KDRBRAFRETRIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7528255-B2 Hydroxy, ω-carboxyaryl substituted diphenyl ureas and dirivatives thereof as raf kinase inhibitors BAYER PHARMACEUTICALS CORPORATION (US) 2009-05-05 US claimed
US-20030139605-A1 Method and/or process for preparing omega-carboxyaryl substituted diphenyl ureas as raf kinas inhibitors BAYER HEALTHCARE LLC 2003-07-24 US claimed
US-7528255-B2 Hydroxy, ω-carboxyaryl substituted diphenyl ureas and dirivatives thereof as raf kinase inhibitors BAYER PHARMACEUTICALS CORPORATION (US) 2009-05-05 US disclosed
US-20030139605-A1 Method and/or process for preparing omega-carboxyaryl substituted diphenyl ureas as raf kinas inhibitors BAYER HEALTHCARE LLC 2003-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030139605-A1 Method and/or process for preparing omega-carboxyaryl substituted diphenyl ureas as raf kinas inhibitors RAF1, BRAF, ARAF RAF1 1/4885KDR 557/4885BRAF 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.